Treatment and Vaccine Development of Mycoplasma Pneumoniae
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT03911440|
Recruitment Status : Recruiting
First Posted : April 11, 2019
Last Update Posted : April 11, 2019
|Condition or disease||Intervention/treatment||Phase|
|Atypical Pneumonia||Drug: Doxycycline Drug: Azithromycin||Not Applicable|
|Study Type :||Interventional (Clinical Trial)|
|Estimated Enrollment :||100 participants|
|Intervention Model:||Parallel Assignment|
|Masking:||None (Open Label)|
|Official Title:||Diagnosis and Treatment of Mycoplasma Pneumoniae and Vaccine Development|
|Actual Study Start Date :||November 10, 2018|
|Estimated Primary Completion Date :||December 31, 2022|
|Estimated Study Completion Date :||December 31, 2022|
Active Comparator: Azithromycin
Azithromycin (10mg/kg/day) is given to children with mycoplasma pneumonia for 3 days.
Azithromycin is given with a dosage of 10 mg/kg/day once a day for 3 days.
Doxycycline (2-4mg/kg/day) is given to children with mycoplasma pneumonia for 5-10 days.
Oral doxycycline is given with a dosage of 2-4 mg/kg/day divided into twice a day for 5-10 days.
- Defervescence [ Time Frame: Up to 10 days ]The timing (days) when fever subsides after treatment
- Hospital stay [ Time Frame: Up to 2 weeks ]The length of hospitalization
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03911440
|Contact: Li-Min Huang, MD, PhD||886-2-23123456 ext email@example.com|
|National Taiwan University Hospital||Recruiting|
|Taipei, Taiwan, 100|